Probatebeta
Company

Robert Ritch MD

As of the edition of 20 October 2026, Robert Ritch MD runs 1 drug; it is on route A at 2 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Went quiet1
Total1

Where it needs a new molecule

Route A at 2 targets, route B at 0 targets.

Three of its 2 rows, by target and route
TargetRoute
ROCK1 Rho-associated protein kinase 1Route A
ROCK2 Rho-associated protein kinase 2Route A

All 2 rows on route A or B

In the product

2 company-target rows on route A or B; 0 are not shown here, and no score is.

See all 2 targets where Robert Ritch MD needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.